−1.630AUD
−374.60 MAUD
1.71 BAUD
552.83 M
About HEALIUS LIMITED
Sector
Industry
CEO
Paul Anderson
Website
Headquarters
Sydney
Employees (FY)
11 K
Founded
1994
ISIN
AU0000033359
FIGI
BBG000BBDQK8
Healius Ltd. engages in the provision of healthcare technology solutions. It operates through the following segments: Pathology, Imaging, and Other. The Pathology segment provides pathology services. The Imaging segment focuses on imaging services from stand-alone imaging sites, hospitals, and medical centers. The Other segment consists of corporate functions. The company was founded by Edmund Gregory Thomas Bateman in 1985 and is headquartered in St. Leonards, Australia.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HLS is 1.210 AUD — it has increased by 0.17% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange HEALIUS LIMITED stocks are traded under the ticker HLS.
HEALIUS LIMITED is going to release the next earnings report on Aug 21, 2024. Keep track of upcoming events with our Earnings Calendar.
HLS stock is 2.52% volatile and has beta coefficient of 1.47. Check out the list of the most volatile stocks — is HEALIUS LIMITED there?
One year price forecast for HEALIUS LIMITED has a max estimate of 1.450 AUD and a min estimate of 1.000 AUD.
HLS earnings for the last quarter are 0.03 AUD whereas the estimation was 0.02 AUD which accounts for 24.69% surprise. Estimated earnings for the next quarter are −0.02 AUD. See more details about HEALIUS LIMITED earnings.
HEALIUS LIMITED revenue for the last quarter amounts to 842.90 M AUD despite the estimated figure of 879.12 M AUD. In the next quarter revenue is expected to reach 847.27 M AUD.
Yes, you can track HEALIUS LIMITED financials in yearly and quarterly reports right on TradingView.
HLS stock has fallen by 1.06% compared to the previous week, the month change is a 1.42% rise, over the last year HEALIUS LIMITED has showed a 57.21% decrease.
HLS net income for the last quarter is −635.80 M AUD, while the quarter before that showed −345.90 M AUD of net income which accounts for −83.81% change. Track more HEALIUS LIMITED financial stats to get the full picture.
Today HEALIUS LIMITED has the market capitalization of 874.95 M, it has increased by 1.13% over the last week.
Like other stocks, HLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HEALIUS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 11.00 K employees. See our rating of the largest employees — is HEALIUS LIMITED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HEALIUS LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HEALIUS LIMITED stock shows the sell signal. See more of HEALIUS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HEALIUS LIMITED future price: according to them, HLS price has a max estimate of 1.45 AUD and a min estimate of 1.00 AUD. Read a more detailed HEALIUS LIMITED forecast: see what analysts think of HEALIUS LIMITED and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HEALIUS LIMITED EBITDA is 355.00 M AUD, and current EBITDA margin is 21.80%. See more stats in HEALIUS LIMITED financial statements.